TCRT (Alaunos Therapeutics) Shiller PE Ratio: (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCRT Alaunos Therapeutics Inc TCRT
27 GF Score
Price $1.49
GF Value $0.82
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alaunos Therapeutics  (NAS:TCRT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alaunos Therapeutics Shiller PE Ratio Related Terms


Alaunos Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Shiller PE Ratio Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alaunos Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TCRT vs MBIO, REVB, GRI: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Shiller PE Ratio falls into.


TCRT
27GF Score
Alaunos Therapeutics Inc TCRT
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alaunos Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Alaunos Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.41/333.9520*333.9520
=-0.410

Current CPI (Jun. 2026) = 333.9520.

Alaunos Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -16.500 241.428 -22.823
201612 -16.500 241.432 -22.823
201703 -22.500 243.801 -30.820
201706 -19.500 244.955 -26.585
201709 -19.500 246.819 -26.384
201712 -19.500 246.524 -26.416
201803 -22.500 249.554 -30.109
201806 -18.000 251.989 -23.855
201809 -19.500 252.439 -25.797
201812 193.500 251.233 257.210
201903 -12.000 254.202 -15.765
201906 -13.500 256.143 -17.601
201909 -64.500 256.759 -83.892
201912 -13.500 256.974 -17.544
202003 -13.500 258.115 -17.466
202006 -13.500 257.797 -17.488
202009 -15.000 260.280 -19.246
202012 -16.500 260.474 -21.155
202103 -15.000 264.877 -18.912
202106 -16.500 271.696 -20.281
202109 -16.500 274.310 -20.088
202112 -7.500 278.802 -8.984
202203 -7.500 287.504 -8.712
202206 -7.500 296.311 -8.453
202209 -6.000 296.808 -6.751
202212 -6.000 296.797 -6.751
202303 -6.300 301.836 -6.970
202306 -5.490 305.109 -6.009
202309 -5.300 307.789 -5.751
202312 -4.900 306.746 -5.335
202403 -1.050 312.332 -1.123
202406 -0.710 314.175 -0.755
202409 -0.700 315.301 -0.741
202412 -0.460 315.605 -0.487
202503 -0.670 319.799 -0.700
202506 -0.630 322.561 -0.652
202509 -0.550 324.800 -0.565
202512 -0.360 324.054 -0.371
202603 -0.590 330.213 -0.597
202606 -0.410 333.952 -0.410

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $1.49 is trading 81.7% above its estimated GF Value™ of $0.82. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Shiller PE Ratio:
  • GF Value™: $0.82 vs. price of $1.49 (81.7% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
27GF Score

Get the complete analysis for TCRT

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$0.82
GF Value